Literature DB >> 16014961

The distal short consensus repeats 1 and 2 of the membrane cofactor protein CD46 and their distance from the cell membrane determine productive entry of species B adenovirus serotype 35.

Christoph Fleischli1, Sandra Verhaagh, Menzo Havenga, Dominique Sirena, Walter Schaffner, Roberto Cattaneo, Urs F Greber, Silvio Hemmi.   

Abstract

The human regulator of complement activation membrane cofactor protein (CD46) has recently been identified as an attachment receptor for most species B adenoviruses (Ads), including Ad type 3 (Ad3), Ad11, and Ad35, as well as species D Ad37. To characterize the interaction between Ad35 and CD46, hybrid receptors composed of different CD46 short consensus repeat (SCR) domains fused to immunoglobulin-like domains of CD4 and a set of 36 CD46 mutants containing semiconservative changes of single amino acids within SCR domains I and II were tested in binding and in Ad35-mediated luciferase transduction assays. In addition, anti-CD46 antibodies and soluble polypeptides constituting various CD46 domains were used in binding inhibition studies. Our data indicate that (i) CD46 SCR I or SCR II alone confers low but significant Ad35 binding; (ii) the presence of SCR I and II is required for optimal binding and transgene expression; (iii) transduction efficiencies equivalent to that of full-length CD46 are obtained if SCR I and II are at an appropriate distance from the cell membrane; (iv) ablation of the N-glycan attached to SCR I has no influence on receptor function, whereas ablation of the SCR II N-glycan results in about a two- to threefold reduction of binding and transgene expression; (v) most putative Ad35 binding residues are located on the same solvent-exposed face of the SCR I or SCR II domain, which are twisted by about 90 degrees ; and (vi) the putative Ad35 binding sites partly overlap with the measles virus binding surface.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014961      PMCID: PMC1181579          DOI: 10.1128/JVI.79.15.10013-10022.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Authors:  M J E Havenga; A A C Lemckert; O J A E Ophorst; M van Meijer; W T V Germeraad; J Grimbergen; M A van Den Doel; R Vogels; J van Deutekom; A A M Janson; J D de Bruijn; F Uytdehaag; P H A Quax; T Logtenberg; M Mehtali; A Bout
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 2.  Protein recognition by cell surface receptors: physiological receptors versus virus interactions.

Authors:  Jia huai Wang
Journal:  Trends Biochem Sci       Date:  2002-03       Impact factor: 13.807

3.  Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector.

Authors:  F Sakurai; H Mizuguchi; T Hayakawa
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

4.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  Flexibility of the adenovirus fiber is required for efficient receptor interaction.

Authors:  Eugene Wu; Lars Pache; Dan J Von Seggern; Tina-Marie Mullen; Yeshi Mikyas; Phoebe L Stewart; Glen R Nemerow
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

6.  Adenovirus type 11 uses CD46 as a cellular receptor.

Authors:  Anna Segerman; John P Atkinson; Marko Marttila; Veronica Dennerquist; Göran Wadell; Niklas Arnberg
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B.

Authors:  S Knaän-Shanzer; I Van Der Velde; M J Havenga; A A Lemckert; A A De Vries; D Valerio
Journal:  Hum Gene Ther       Date:  2001-11-01       Impact factor: 5.695

8.  Early steps of clathrin-mediated endocytosis involved in phagosomal escape of Fcgamma receptor-targeted adenovirus.

Authors:  Oliver Meier; Michele Gastaldelli; Karin Boucke; Silvio Hemmi; Urs F Greber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

9.  Identification of the streptococcal M protein binding site on membrane cofactor protein (CD46).

Authors:  Eleni Giannakis; T Sakari Jokiranta; Rebecca J Ormsby; Thomas G Duthy; Dean A Male; Dale Christiansen; Vince A Fischetti; Chris Bagley; Bruce E Loveland; David L Gordon
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

10.  Human Herpesvirus 6 and Measles Virus Employ Distinct CD46 Domains for Receptor Function.

Authors:  Heather L Greenstone; Fabio Santoro; Paolo Lusso; Edward A Berger
Journal:  J Biol Chem       Date:  2002-08-08       Impact factor: 5.157

View more
  22 in total

Review 1.  Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism.

Authors:  J Michael Mathis; Phoebe L Stewart; Zheng B Zhu; David T Curiel
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

2.  Structural variations in species B adenovirus fibers impact CD46 association.

Authors:  Lars Pache; Sangita Venkataraman; Vijay S Reddy; Glen R Nemerow
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

Review 3.  Emerging roles and new functions of CD46.

Authors:  M Kathryn Liszewski; Claudia Kemper; Jeffrey D Price; John P Atkinson
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

4.  A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells.

Authors:  Sebastian Tuve; Hongjie Wang; Carol Ware; Ying Liu; Anuj Gaggar; Kathrin Bernt; Dmitry Shayakhmetov; Zongyi Li; Robert Strauss; Daniel Stone; André Lieber
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

Review 5.  CD46 processing: a means of expression.

Authors:  Siobhan Ni Choileain; Anne L Astier
Journal:  Immunobiology       Date:  2011-07-13       Impact factor: 3.144

6.  Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection.

Authors:  Hung V Trinh; Guillaume Lesage; Venus Chennamparampil; Benedikt Vollenweider; Christoph J Burckhardt; Stefan Schauer; Menzo Havenga; Urs F Greber; Silvio Hemmi
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

7.  Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35.

Authors:  Stefan Kälin; Beat Amstutz; Michele Gastaldelli; Nina Wolfrum; Karin Boucke; Menzo Havenga; Fabienne DiGennaro; Nicole Liska; Silvio Hemmi; Urs F Greber
Journal:  J Virol       Date:  2010-03-17       Impact factor: 5.103

8.  An arginine switch in the species B adenovirus knob determines high-affinity engagement of cellular receptor CD46.

Authors:  B David Persson; Steffen Müller; Dirk M Reiter; Benedikt B T Schmitt; Marko Marttila; Chris Vanessa Sumowski; Sabine Schweizer; Ulrike Scheu; Christian Ochsenfeld; Niklas Arnberg; Thilo Stehle
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

9.  Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob.

Authors:  Hongjie Wang; Yen-Chywan Liaw; Daniel Stone; Oleksandr Kalyuzhniy; Imameddin Amiraslanov; Sebastian Tuve; Christophe L M J Verlinde; Dmitry Shayakhmetov; Thilo Stehle; Steve Roffler; André Lieber
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

Review 10.  Innate immunity to adenovirus.

Authors:  Rodinde Hendrickx; Nicole Stichling; Jorien Koelen; Lukasz Kuryk; Agnieszka Lipiec; Urs F Greber
Journal:  Hum Gene Ther       Date:  2014-04-08       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.